# Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

> **NCT00006441** · NA · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 398 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lamivudine/Zidovudine
- **DRUG:** Nelfinavir mesylate
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT00006441
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2015-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006441, "Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*